Global Biotech & Pharma Licensing Activity up in Q2 2010

NORWOOD, MA -- (Marketwire) -- 07/27/10 -- BioPharm Insight™, a part of The Financial Times Group, in its Biotechnology and Pharmaceutical Licensing Agreement Report shows 152 agreements valued at USD 9.4bn, an increase of 10% by value from Q1 2010, in which 139 agreements with a total value of USD 8.5bn were announced. The agreement between TransTech Pharma and Forest Laboratories involving glucokinase activator program, for the treatment of diabetes, was the largest deal in Q2 2010, valued at USD 1.1bn.

Cancer and Central Nervous System continue to be the most active therapeutic categories by volume of deals in Q2 2010. In terms of deal value, licensing agreements in the Metabolism and Cancer areas have moved to the leading positions in Q2 2010, replacing Respiratory and Immunomodulation deals, which have dropped to sixth and twelfth positions, respectively.

Download the full report and data from www.biopharminsight.com

About BioPharm Insight's Drug Licensing Deal Information:
BioPharm Insight's Licensing Agreement Database summarizes the most material information from company press releases and updates, financial statements, regulatory filings, and news articles from the present day and dating back to 1984. The deal summaries provide scope and background of the agreement, and financial & commercial terms of agreements. The database has seen over 11,000 drug licensing updates since inception including milestone & royalty payments, and terminations. BioPharm Insight's Robust Database Search Capabilities include:

• Twenty-five different search parameters help you find the information you are looking for in seconds
• Search by therapeutic area, deal type, financial information, development phase or keyword
• Edit and save search details, download in Microsoft Excel, send via mail, and print capabilities
• Search over 70,000 key contacts with emails and biographies within research & development, management, and sales & marketing departments
• 10k exhibit postings are also available

BioPharm Insight is a wholly-owned subsidiary of the Financial Times Group, publisher of the Financial Times newspaper and FT.com. FT Group is a division of Pearson plc (NYSE: PSO), the international media group. BioPharm Insight provides daily intelligence on the pharmaceutical and biotech industry. For product and sales information, visit: www.biopharminsight.com

Add to Digg Bookmark with del.icio.us Add to Newsvine